Navigation Links
Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
Date:12/21/2010

MOUNTAIN VIEW, Calif., Dec. 21, 2010 /PRNewswire/ -- Based on its recent analysis of the surface functionalization technologies market, Frost & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences with the 2010 Enabling Technology of the Year Award for Surface Functionalization Technologies. The company's Semprus Platform is a high-performance biofunctional surface modification designed to reduce the complications associated with implanted medical devices while improving healthcare cost efficiencies.

(Logo:  http://photos.prnewswire.com/prnh/20081117/FSLOGO)

"A majority of hospital-acquired infections contracted each year originate with the colonization of bacteria on implantable medical devices, which provide a good surface for bacterial growth," said Frost & Sullivan Research Analyst Prasanna Vadhana. "Owing to the rapid growth in the use of medical device implants and the lack of improved surface technologies, the medical device industry is in dire need of next-generation devices that significantly improve patient outcomes."

To meet this need, Semprus BioSciences has developed the Semprus Platform based on a bioinert, covalently-bonded surface modification that reduces the attachment of bacteria, fungus, platelets and blood proteins to a device.

"Semprus BioSciences' platform is able to adapt to diverse substrates such as polyurethane, silicone and titanium, thus paving the way for next-generation products with improved clinical benefits across the medical spectrum," said Vadhana. "The versatility of this technology creates avenues to address multiple products ranging from contact lenses and orthopedic fixation devices to hernia repair meshes and pacemakers, and many others."

In December 2010, Semprus BioSciences completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. This funding adds to an $8 million Series A financing round in 2008 that was co-led by 5AM Ventures and Pangaea Ventures, as well as $2.5 million in seed capital raised. Semprus BioSciences has secured global licenses from the Massachusetts Institute of Technology (MIT) and the University of Washington. The company also holds numerous intellectual property filings and grants from the Department of Defense, the National Institutes of Health (NIH) and the National Science Foundation (NSF), for a total of $2.5 million in grant funding since 2008.

Frost & Sullivan's independent technology research confirms that Semprus BioSciences' unique technology platform is the first non-leaching single surface modification designed to simultaneously reduce microbial adhesion and thrombus formation (blood clots) on medical devices with multi-month efficacy. Based on these factors, Frost & Sullivan has selected Semprus BioSciences to receive the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies.

Each year, Frost & Sullivan presents this award to the company that has developed a pioneering technology that not only enhances current products but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient's technology.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

About Semprus BioSciencesSemprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. The company's innovative, multi-faceted Semprus technology signifies a breakthrough in medical device technology. Semprus' current focus is to develop a vascular access catheter with the first single surface modification that is designed to simultaneously reduce microbial adherence and thrombus accumulation over the life of the device. Visit http://www.semprusbio.com for additional information.

About Frost & SullivanFrost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.awards.frost.com.Contact:Jake Wengroff210.247.3806jake.wengroff@frost.com
'/>"/>

SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes Merge Healthcares Clinical Imaging Management Solution as Game Changing Technology
2. Frost & Sullivan Award Highlights Hybridyne Technologies Outstanding Technology Innovation
3. Frost & Sullivan Recognizes Visage Imaging, Inc. for its Medical Imaging Informatics in Healthcare Innovation
4. Frost & Sullivan: Strategic Partnerships Crucial to Medical Device Success
5. Frost & Sullivan Global Product Line Strategy of the Year Award Presented to Xenemetrix
6. Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution
7. Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan
8. Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products
9. U.S. Ambulatory Electronic Health Record Market Presents Significant Opportunities and Risks for Vendors, Finds Frost & Sullivan
10. Increasing Potential for RIS-driven PACS Modules in Europe, Finds Frost & Sullivan
11. Frost & Sullivan Recognizes QRxPharma for Innovative Pain Relief Product MoxDuo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Calif. , March 29, 2017  Designers of ... significantly reduce solution size by 50% and extend battery ... ) power management integrated circuit (PMIC) from Maxim Integrated ... PMIC supports a low input voltage of just 0.7V ... Air and Silver Oxide, as well as the more ...
(Date:3/29/2017)... , March 29, 2017  NuVasive, Inc. (NASDAQ: ... transforming spine surgery with minimally disruptive, procedurally-integrated solutions, ... 510(k) clearance of the CoRoent® Small Interbody™ System ... levels in the cervical spine. This marks the ... be used at up to four contiguous levels. ...
(Date:3/29/2017)... HEIGHTS, Utah , March 29, 2017 /PRNewswire/ ... ) announced today the appointment of Cynthia ... Operations.  Cyndi will be responsible for leading Dynatronics ... organization and will report to Dynatronics, CEO ... Cyndi,s appointment concludes an extensive search process conducted ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional ... it has enlisted New York City-based sports and entertainment marketing firm Leverage Agency ... sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ever title ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy ... "Wonder Spice", it has been used for thousands of years. , "The West has ... author of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... provides insight into the challenges employers face in trying to balance both short-term ... employee benefits programs? Adding to the growing complexity, companies are finding that ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):